
Lisa Aniek de Jong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1827526/publications.pdf Version: 2024-02-01



LISA ANIEK DE LONG

#	Article	IF	CITATIONS
1	Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands. Journal of Medical Economics, 2021, 24, 1149-1163.	2.1	2
2	Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands. PharmacoEconomics - Open, 2020, 4, 321-330.	1.8	5
3	Author's Reply. Value in Health, 2020, 23, 675-676.	0.3	Ο
4	Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. BMJ Open, 2020, 10, e039057.	1.9	7
5	Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application ofÂthe Efficiency Frontier. Value in Health, 2019, 22, 1119-1127.	0.3	13
6	Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PLoS ONE, 2019, 14, e0222658.	2.5	21
7	Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis. Journal of Medical Economics, 2019, 22, 306-318.	2.1	10
8	Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. European Journal of Health Economics, 2018, 19, 957-965.	2.8	9